Saturation Mutagenesis of Lysine 12 Leads to the Identification of Derivatives of Nisin A with Enhanced Antimicrobial Activity by Molloy, Evelyn M. et al.
Saturation Mutagenesis of Lysine 12 Leads to the
Identification of Derivatives of Nisin A with Enhanced
Antimicrobial Activity
Evelyn M. Molloy1, Des Field1, Paula M. O’ Connor2,3, Paul D. Cotter2,3*, Colin Hill1,2*, R. Paul Ross2,3
1Department of Microbiology, University College Cork, Cork, Ireland, 2Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland, 3 Teagasc Food Research
Centre, Moorepark, Fermoy, Co. Cork, Ireland
Abstract
It is becoming increasingly apparent that innovations from the ‘‘golden age’’ of antibiotics are becoming ineffective,
resulting in a pressing need for novel therapeutics. The bacteriocin family of antimicrobial peptides has attracted much
attention in recent years as a source of potential alternatives. The most intensively studied bacteriocin is nisin, a broad
spectrum lantibiotic that inhibits Gram-positive bacteria including important food pathogens and clinically relevant
antibiotic resistant bacteria. Nisin is gene-encoded and, as such, is amenable to peptide bioengineering, facilitating the
generation of novel derivatives that can be screened for desirable properties. It was to this end that we used a site-
saturation mutagenesis approach to create a bank of producers of nisin A derivatives that differ with respect to the identity
of residue 12 (normally lysine; K12). A number of these producers exhibited enhanced bioactivity and the nisin A K12A
producer was deemed of greatest interest. Subsequent investigations with the purified antimicrobial highlighted the
enhanced specific activity of this modified nisin against representative target strains from the genera Streptococcus, Bacillus,
Lactococcus, Enterococcus and Staphylococcus.
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Introduction
Bacteriocins are small (,4 kDa) ribosomally-synthesised pep-
tides secreted by bacteria into their environment and which inhibit
other bacteria. They can have a broad (effective against multiple
genera) or narrow (effective only against specific species) activity
spectra. Producer organisms also have specific immunity proteins
to protect them from the action of their own bacteriocin. Nisin is
an example of the class I bacteriocins, distinguished by virtue of
containing unusual amino acids as a result of enzyme-mediated
post-translational modification [1]. This particular group of Class I
are known as the lanthionine-containing antibiotics or ‘lanti-
biotics’ [2]. In lantibiotics, the unusual amino acids dehydroa-
lanine (Dha) and dehydrobutyrine (Dhb) are formed by dehydra-
tion of serine and threonine residues, respectively. Subsequently,
specific addition reactions between cysteine residues and some of
these unsaturated amino acids result in the formation of the
characteristic lanthionine and b-methyllanthionine residues. The
thio-ether bridges of these residues act as intramolecular cross-
links, resulting in the introduction of ‘rings’ in the mature
bacteriocin [3,4,5].
Six natural nisin variants have been identified to date, namely
nisin A [6], nisin Z [7], nisin Q [8], nisin F [9] (produced by strains
of Lactococcus lactis), and nisin U and nisin U2 (produced by strains
of Streptococcus uberis) [10]. Nisin A contains 34 amino acids and five
post-translationally incorporated (b-methyl)lanthionine rings
(Fig. 1) [4]. It displays antibacterial activity against a wide range
of Gram-positive bacteria, including food-borne pathogens such as
staphylococci, bacilli and clostridia. Studies have revealed that
nisin and several other lantibiotics use the membrane-bound
peptidoglycan precursor lipid II as a docking molecule [11]. In the
case of nisin, this facilitates two bactericidal activities, the
inhibition of cell wall biosynthesis and disruption of the cell
membrane due to pore formation [12,13,14]. This dual activity is
possible due to the presence of two structured domains, both of
which are amphipathic in character [15]. The N-terminal domain,
containing rings A, B, and C, is linked to the C-terminal
intertwined rings D and E by a flexible hinge region consisting
of three residues (N20-M21-K22; Fig. 1). Structural studies have
established that rings A and B form a ‘cage’ that facilitates binding
of the pyrophosphate moiety of lipid II, thus interfering with cell
wall synthesis [16]. This binding allows the C-terminal rings D and
E, via the flexible hinge region, to form pores in the target
membrane, causing cell death by rapid efflux of ions and
cytoplasmic solutes [17,18].
Although nisin has been studied extensively from a fundamental
perspective, there has been an even greater focus on its
commercial application. Nisin provides an excellent solution to
consumer demands for safe food with a long shelf-life, but without
the need for chemical preservatives. Nisin has a long record of safe
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use and is used in a variety of foods such as canned foods,
processed cheese and dairy products [19,20]. It has been approved
by the EU as additive E234, as well as by the World Health
Organisation (WHO) and the US Food and Drug Administration
(FDA). In addition to food-related applications, nisin has been
investigated as a chemotherapeutic agent given its high potency
(with activity at nanomolar concentrations) [21,22] and its stable,
non-cytotoxic nature [23]. As nisin is active against the principle
Gram-positive pathogens that cause bovine mastitis, an infection
of the udder that is both persistent and costly to treat, it has also
been incorporated into a number of commercial products as an
efficacious and non-toxic alternative to antibiotics [24,25,26].
Finally, nisin shows promise in suppressing multi-drug resistant
infections such as methicillin-resistant Staphylococcus aureus (MRSA),
heterogeneous vancomycin-intermediate S. aureus (hVISA), and
vancomycin-resistant Enterococcus (VRE) [22,27].
Because lantibiotics are gene-encoded and ribosomally synthe-
sized (as opposed to being assembled via multi-step, multi-enzyme
processes as is the case for non-ribosomally synthesised peptide
antibiotics), they are amenable to relatively simple bioengineering
strategies designed to improve their production and effectiveness
[4,5,28,29]. Nisin has been the focus of bioengineering in order to
elucidate the relationship between the structure and function of
the molecule, as well as with a view to improving functional
properties of the peptide [30]. Bioengineering has been fruitful
with respect to the introduction of mutations that have a positive
impact on the physico-chemical properties of nisin, including
better solubility [31,32], improved stability [32] and an enhanced
ability to diffuse through complex polymers [33]. Initial success
with regard to increasing the potency of nisin came with the
creation of bioengineered nisin derivatives with superior antimi-
crobial activity against some non-pathogenic targets [13,34,35,36].
Perhaps more importantly, nisin Z N20K and M21K were the first
bioengineered nisin derivatives that were enhanced against
pathogenic bacteria, namely Shigella, Pseudomonas and Salmonella
species [32]. The first nisin derivatives to be created with improved
activity against target Gram-positive pathogens were nisin A
N20P, M21V, K22S and K22T [37]. Nisin M21V has since been
designated as Nisin V and exhibits enhanced activity a wide range
of targets, including numerous drug resistant strains [38]. Nisin V
outperformed wild-type nisin in a food model with respect to the
control of the food pathogen Listeria monocytogenes, a noteworthy
outcome in light of the high innate resistance of L. monocytogenes to
nisin [38]. Recently, nisin A S29G, S29A, S29D, S29E derivatives
were described that displayed increased potency against a range of
Gram-positive targets, with S29G and S29A being the first nisin
derivatives found to display enhanced activity against both Gram-
positive and Gram-negative bacteria [39]. Taken together, these
studies demonstrate that bioengineering can both improve the
activity of nisin against sensitive cells as well as alter its target
spectrum.
Given the previous positive outcomes from manipulating the
nisin ‘hinge’ region [32,37], we turned our attentions to K12 of
nisin A, a residue which could serve as a smaller flexible region
between rings B and C (Fig. 1). A site-saturation mutagenesis
approach in a L. lactis NZ9800 background led to the discovery of
several derivatives of interest with one in particular, K12A,
displaying enhanced specific activity against numerous Gram-
positive microorganisms of food and/or clinical significance. This
discovery further highlights the benefits of bioengineering nisin to
generate derivatives with superior antimicrobial activity against
specific problematic microorganisms.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. L. lactis strains were grown at 30uC in M17 broth (Oxoid)
supplemented with 0.5% glucose (GM17) or on GM17 agar (1.5%
w/v). C. sakazakii, Salmonella and E. coli strains were grown at 37uC
in Luria-Bertani (LB) broth with vigorous shaking or on LB agar.
Chloramphenicol was used at 10 mg/ml for L. lactis and E. coli
where necessary. Enterococcus strains were grown at 37uC in GM17
broth or on GM17 agar. Streptococcus strains were grown in Tryptic
Soy Broth (TSB) (Merck) or on TSB agar at 37uC (supplemented
with 0.3% (w/v) yeast extract (Oxoid) in the case of S. pyogenes
DSM 11728; grown microaerophilically), except S. pyogenes DSM
2071 which was grown anaerobically (Anaerocult A; Merck,
Darmstadt, Germany) in Brain Heart Infusion (BHI) broth (Oxoid)
or on BHI agar at 37uC. Staphylococcus and Bacillus strains were
grown at 37uC in BHI broth or on BHI agar. Drug resistant strains
(i.e. VREs, hVISAs and MRSAs) were grown in Mueller-Hinton
(MH) broth (Oxoid) or on MH agar at 37uC. Listeria strains were
grown in BHI broth or on BHI agar at 37uC.
Site-saturation and site-directed mutagenesis of position
K12 of nisin A
Saturation mutagenesis of the lysine codon at position 12 of nisA
was performed by PCR using plasmid pDF05 [37] as template
(Table 1) and oligonucleotides NisK12degFOR and NisK12de-
gREV (Table 2). These oligonucleotides contain an NNK codon
in place of the native AAA codon, in theory resulting in the
substitution of the native residue with all 19 other standard amino
acids [40,41]. PCR amplification was performed as previously
described [37]. Following introduction into the E. coli Top10
intermediate host, plasmid DNA was isolated and sequenced
(MWG Operon, Germany) with pCI372For (Table 2) to confirm
mutagenesis of the specific codon. Plasmid DNA was introduced
by electroporation into the expression strain L. lactis NZ9800.
Approximately 150 transformants were subjected to colony mass
spectrometry (CMS), which in most instances could be used to
unequivocally determine the nature of the amino acid substitu-
Figure 1. Structure of nisin A. The structure of nisin A is depicted, showing the location of its five (b-methyl)lanthionine rings (A–E) and modified
residues dehydroalanine (yellow) and dehydrobutyrine (green). Position K12 is highlighted in red and the hinge region is boxed.
doi:10.1371/journal.pone.0058530.g001
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Table 1. Strains and plasmids used in this study.
Strain/plasmids Relevant characteristics Source/reference
Strains
Lactococcus lactis NZ9800 L. lactis NZ9700 DnisA [63,64]
L. lactis NZ9800 pDF05 Wild-type nisin A producer [37]
Escherichia coli Top10 Intermediate cloning host Invitrogen
Indicator Organisms
Enterococcus faecalis 5152 Indicator strain DPC Collection
E. casseliflavus 5053 Indicator strain DPC Collection
E. faecium VRE EC 533 Indicator strain BSAC
E. faecium VRE EC 725 Indicator strain BSAC
E. faecium 5119 Indicator strain DPC Collection
E. faecium 5137 Indicator strain DPC Collection
E. durans 5133 Indicator strain DPC Collection
Streptococcus dysgalactiae UCC 5003 Indicator strain UCC Culture Collection
S. dysgalactiae GroupC #2 Indicator strain UCC Culture Collection
S. pyogenes DSM 2071 Indicator strain DSMZ
S. pyogenes DSM 11728 Indicator strain DSMZ
S. pyogenes NCDO 2381 Indicator strain NCDO
S.agalactiae ATCC 13813 Indicator strain ATCC
S.agalactiae Group B Indicator strain UCC Culture Collection
S.agalactiae COH31rs Indicator strain DPC Collection
S. mitis UCC 5001 Indicator strain UCC Culture Collection
Bacillus cereus NCIMB 700578 Indicator strain NCIMB
B. cereus NCIMB 700579 Indicator strain NCIMB
B. cereus NCIMB 700827 Indicator strain NCIMB
B. cereus DPC 6089 Indicator strain DPC Collection
B. cereus DPC 5334 Indicator strain DPC Collection
B. cereus NCIMB 700577 Indicator strain NCIMB
B. subtilis UCC 5002 Indicator strain UCC Culture Collection
L. lactis ssp cremoris HP Indicator strain UCC Culture Collection
L. lactis MG 1363 Indicator strain UCC Culture Collection
Staphylococcus aureus hVISA 32679 Indicator strain BSAC
S. aureus hVISA 32652 Indicator strain BSAC
S. aureus ST MRSA 534 Indicator strain BSAC
S. aureus ST MRSA 528 Indicator strain BSAC
S. aureus ST MRSA 530 Indicator strain BSAC
S. aureus RF 122 Indicator strain DPC Collection
S. aureus DPC 5247 Indicator strain DPC Collection
S. aureus DPC 5971 Indicator strain DPC Collection
S. aureus NCDO 1499 Indicator strain DPC Collection
Listeria monocytogenes EGD-e Indicator strain; serotype 1/2a [65]
L. monocytogenes EGD-e DvirR Indicator strain; DvirR [51]
L. monocytogenes EGD-e DtelA Indicator strain; DtelA [66]
L. monocytogenes L028 Indicator strain; clinical isolate UCC Culture Collection
L. monocytogenes L028 DgadA Indicator strain; DgadA [67]
L. monocytogenes L028.pORI.lmo1021 Indicator strain Guinane et al., unpublished
L. monocytogenes 10403S Indicator strain UCC Culture Collection
L. monocytogenes 33410 Indicator strain; clinical isolate; serotype 4b ILSI
L. monocytogenes 33423 Indicator strain; food isolate; serotype 1/2b ARS
Cronobacter sakazaki DPC 6440 Gram-negative indicator strain DPC Collection
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tions. DNA sequencing with pCI372For (Table 2) was employed
in cases where further clarification was needed.
Site-directed mutagenesis of the nisA gene was achieved using
pDF05-K12A as template (Table 1), the relevant primers (Table 2)
and PCR amplification as before. To detect altered Top10
transformants, candidates were screened by PCR using a specific
‘check’ primer and pCI372Rev (Table 2). Plasmids from
candidates were sequenced using pCI372Rev (Table 2) to verify
the deliberate mutation and to confirm no other changes had been
introduced, then used to transform NZ9800.
Deferred antagonism assays
Deferred antagonism assays for bioactivity determination were
performed as previously described [39].
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometric analysis
Colony mass spectrometry (CMS was performed with an Axima
TOF2 MALDI-TOF mass spectrometer (Shimadzu Biotech,
Manchester, UK) in positive-ion reflectron mode as previously
described [39]. In the case of purified peptide, a small amount of
lyophilised peptide resuspended in 70% 2-propanol 0.1% triflour-
oacetic acid (TFA) was used for mass spectrometric (MS) analysis.
Reverse phase-high performance liquid chromatography
(RP-HPLC) purification of nisin and derivatives
Purified nisin A (nisin) and its derivatives were obtained in a
modified version of a previously employed protocol [38]. The
Phenomenex C12 RP-HPLC column (Jupiter 4 m proteo 90 A˚,
250 X 10.0 mm, 4 mm) was developed in a gradient of 30%
acetonitrile (ACN) 0.1% TFA to 50% ACN containing 0.1% TFA
over 5–40 min, at a flow rate of 1.8 ml/min. In order to facilitate
a comparison of production levels, identical purification steps were
employed and production quantified on the basis of peak areas
obtained during RP-HPLC as calculated with Shimadzu class VP
software (Shimadzu Biotech, Manchester, UK). The gradient for
separation of K12S/Dha and K12T/Dhb was 35% ACN 0.1%
TFA to 45% ACN 0.1% TFA over 5–40 min, at a flow rate of
1.8 ml/min. Fractions containing peptide were collected after
each RP-HPLC run, pooled and the ACN removed by rotary
evaporation. Lyophilised peptide was stored at 220uC.
Minimum inhibitory concentration assays
Minimum inhibitory concentration (MIC) determinations were
performed as previously described [39]. Wild-type nisin and nisin
mutant peptides were adjusted to a starting concentration of
30 mM (Enterococcus faecalis and casseliflavus), 10 mM (Streptococcus,
Bacillus, MRSA), 5 mM (Enterococcus faecium VRE) or 500 nM
(Lactococcus) and two-fold serial dilutions of each peptide were
added to the target strain. After incubation for 16 h under the
relevant conditions, the MIC was read as the lowest peptide
concentration causing inhibition of visible growth.
Gram-negative agarose gel diffusion assay
Equimolar amounts of purified nisin A and K12A (40 mM) were
assessed for bioactivity against representative Gram-negative
species as previously described [39].
Results
Creation and mass spectrometric analysis of a bank of
nisin K12 derivatives
A site-saturation mutagenesis-based strategy was undertaken to
generate a bank of producers of bioengineered nisin derivatives in
which residue K12 was converted to every other natural amino
acid. This strategy proved successful in that 15 of the 19 potential
residue conversions were identified. Site-directed mutagenesis was
employed to create the remaining derivatives (K12N, K12I, K12D
and K12H), resulting in the generation of a complete ‘‘K12X’’
bank of producers (Table 3). It is notable that the K12S and K12T
substitutions introduce hydroxyl residues, which could potentially
become substrates for the lanthionine modification machinery to
produce Dha or Dhb, respectively. Analysis of these derivatives by
CMS confirmed that modification occurs to some degree in that
we detected masses corresponding to Dha and Dhb, in addition to
masses indicating the presence of the unmodified residues
(Table 3). In the case of the K12D derivative, a peptide of the
corresponding mass could not be detected by CMS, indicating a
detrimental impact on production. CMS analysis of the K12C
derivative showed that the newly incorporated cysteine remains in
an unmodified form.
Bioactivity of the nisin A K12X bank
The bioactivity of the 19 K12X derivatives was tested against a
standard sensitive indicator strain (L. lactis HP) by deferred
antagonism assays, with the sizes of the zones of inhibition being
assessed relative to that of the corresponding wild-type nisin A
producer (Table 3). Bioactivity reflects the overall activity of
producer strains and does not discriminate between effects due to
increased/decreased specific activity, altered peptide production
levels, or effects on other physico-chemical properties such as
diffusion in agar. Assaying for bioactivity provides a valuable initial
Table 1. Cont.
Strain/plasmids Relevant characteristics Source/reference
Strains
Salmonella enterica serovar Typhimurium UK1 Gram-negative indicator strain UCC Culture Collection
E. coli 0127:H6 Gram-negative indicator strain UCC Culture Collection
Plasmids
pDF05 pCI372 with nisA under its own promoter [37]
pDF05-K12A pDF05 with K12A substitution (GCT) in nisA This study
DPC: Dairy Products Research Centre, Moorepark; UCC: University College Cork; NCDO: National Collection of Dairy Organisms; DSMZ: German Collection of
Microorganisms and Cell Cultures; ATCC: American Type Culture Collection; NCIMB: National Collection of Industrial, Food and Marine Bacteria; BSAC: British Society for
Antimicrobial Chemotherapy; ILSI: International Life Science Institute (MartinWiedmann), ARS: Agricultural Research Service, U.S. Department of Agriculture (Todd Ward).
doi:10.1371/journal.pone.0058530.t001
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screen to facilitate the identification of derivatives in which
beneficial changes have occurred. Indeed, bioactivity was found to
be significantly enhanced in the cases of K12A, K12S, K12T and
K12P (Table 3).
Bioactivity spectrum of lead nisin K12X derivatives
Because the nisin K12A, K12S and K12T producers had the
highest bioactivity levels (.125% compared to the wild-type
control), they were selected for further analysis. In order to gain an
insight into target specificity, their bioactivity levels were assessed
against 42 target strains corresponding to 13 species of food and/
or clinical relevance (Table 4). Although bioactivity was signifi-
cantly enhanced against most Gram-positive strains tested, it is
important to note that the level of enhanced activity shown by
each derivative was strain variable. In the case of L. monocytogenes,
all displayed bioactivity equal to or less than the wild-type
producer (Table 4), with the antimicrobial sensitive DvirR mutant
of L. monocytogenes EGDe being an exception to this general trend.
While the K12A, K12S and K12T producers show a similar
spectrum of bioactivity, the K12A derivative consistently showed
the greatest bioactivity. Furthermore, significantly enhanced
bioactivity for K12A was evident against every strain from 5 of
the 6 genera tested, excepting L. monocytogenes as previously
mentioned. The K12A, K12S and K12T producers were not
active against the wild-type strain (data not shown).
Purification of nisin K12A, K12S, K12Dha, K12T and
K12Dhb
The fact that the bioactivity of the K12A, K12S and K12T
producers is generally not improved against strains of L.
monocytogenes suggested that their superior bioactivity against other
targets was most likely a consequence of enhanced specific activity
against these targets, rather than a general enhancement arising
from increased production and/or diffusion. To confirm this, nisin
K12A, K12S and K12T peptides were purified by RP-HPLC to
allow quantification of their specific activity by MIC determina-
tion.
Nisin K12A was purified by the RP-HPLC protocol routinely
employed to purify nisin and was found to be produced at similar
levels as nisin A is produced by the wild-type strain (data not
shown). The K12A peptide was stable during purification,
lyophilisation and subsequent storage as determined by MS (data
not shown). In the case of K12S and K12T, the standard RP-
HPLC protocol yielded a single peak which, on the basis of MS,
contained a mixture of K12S/Dha or K12T/Dhb as expected
(data not shown). The production levels of K12S/Dha and K12T/
Dhb were comparable to that of the wild-type producer (data not
shown). Following optimisation of the solvent gradient, the two
forms were successfully separated (Fig. 2). Interestingly, the degree
of modification depends on the identity of the newly-incorporated
residue, in that the ratio of K12S produced relative to K12Dha
was approximately 2:1, while that of K12T to K12Dhb was
approximately 1:2 (Fig. 2). Unfortunately, MS indicated that the
K12S, K12Dha, K12T and K12Dhb peptides were susceptible to
rapid oxidation (characteristic +16 kDa mass observed; data not
shown), despite the use of a variety of strategies designed to
minimise this phenomenon.
Specific activity determination of nisin K12A
In the absence of completely unoxidised peptides, the partially
oxidised K12S, K12Dha, K12T and K12Dhb peptides were
employed for subsequent MIC determination. In each instance
specific activity was not enhanced relative to that of nisin against L.
lactis HP (data not shown), which is not surprising given that
oxidation of nisin is known to affect its antimicrobial activity [42].
In contrast, MIC determination assays established that K12A
displayed a four-fold enhanced potency against L. lactis HP (K12A,
15.6 nM; wild-type, 62.5 nM; Table 5). As a consequence of the
significantly greater bioactivity of the K12A producer against a
broad range of targets, the relative ease with which the K12A
peptide was purified, and the establishment that specific activity
Table 2. Oligonucleotides used in this study.
Primer name Sequence
NisK12degFOR 59- PHO CCCGGTTGTNNKACAGG GCTCTGATGGGTTGTAACATG -39
NisK12degREV 59- AGCTCCTGTMNNACAACCGGGTGTACATAGCGAAATACT -39
pCI372FOR 59- CGGGAAGCTAGAGTAAGTAG -39
pCI372Rev 59- ACCTCTCGGTTATGAGTTAG -39
K12HFor 59- CCCGGTTGTcacACAGGAGCTCTGATGG -39
K12HRev 59- AGCTCCTGTgtgACAACCGGGTGTACATAGC -39
K12Hcheck 59- TATGTACACCCGGTTGTcac -39
K12DFor 59- CCCGGTTGTGacACAGGAGCTCTGATGG -39
K12DRev 59- AGCTCCTGTgtCACAACCGGGTGTACATAGC -39
K12Dcheck 59- TATGTACACCCGGTTGTGac -39
K12NFor 59- CCCGGTTGTaaTACAGGAGCTCTGATGG -39
K12NRev 59- AGCTCCTGTAttACAACCGGGTGTACATAGC -39
K12Ncheck 59- TATGTACACCCGGTTGTaa -39
K12IFor 59- CCCGGTTGTatcACAGGAGCTCTGATGG -39
K12IRev 59- CCCGGTTGTatcACAGGAGCTCTGATGG -39
K12Icheck 59- TATGTACACCCGGTTGTatc- 39
PHO indicates 59 phosphate modification. Underlined sequences represent degenerate codon (N=A+C+G+T, K =G+T, M=A+C). Lower-case letters indicate site-directed
mutation.
doi:10.1371/journal.pone.0058530.t002
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against HP was enhanced, nisin K12A was selected for further
investigation. Its specific activity was assessed against a larger
selection of targets, including representative strains of Enterococcus,
Streptococcus, Bacillus and Staphylococcus, as well as an additional
Lactococcus strain. In all cases, K12A was found to be 2–4 fold more
active than nisin (Table 5).
Although the activity of nisin against the majority of Gram-
negative bacteria is low in the absence of other stress factors such
as chelating agents [43], previous mutational studies have
identified specific derivatives with enhanced anti-Gram-negative
activity [32,39]. Here, an agarose-based well diffusion assay was
employed [39] in order to compare the bioactivity of purified nisin
and K12A against three Gram-negative strains. The results
showed that the bioactivity of K12A against E. coli 0127:H6 was
similar to that of nisin, but that the activity of the K12A peptide
was reduced against Cronobacter sakazakii DPC6440 and Salmonella
enterica serovar Typhimurium UK1 (Table 6).
Discussion
In this study, a combination of site-saturation and site-directed
mutagenesis was employed to generate a bank of nisin A
derivatives in which K12 was substituted with all other standard
amino acids. In addition to identifying promising derivatives
(namely K12A, K12S, K12T, K12P), determination of the
bioactivity of the K12X bank against L. lactis HP provided an
indication of the tolerance of this position to substitution (Table 3).
Overall, the K12 position of nisin was found to be very amenable
to change, which is somewhat unexpected given that a lysine at
this position is conserved across the six known natural nisin
variants. The consequences of K12 mutagenesis can be grouped
according to the nature of the newly incorporated residue. Until
recently, the detrimental effects of introducing negatively charged
residues into the cationic nisin [32,37] were attributed to the
importance of positive charge in the initial attraction of many
cationic peptides to the cell envelope. However, the identification
of the enhanced derivatives S29D and S29E demonstrated that the
outcome varies depending on the location at which substitution
occurs [39]. Indeed, the K12E and K12D derivatives had no
detectable bioactivity, with the production of K12D being
significantly diminished, while K12E is produced but is inactive
(Table 3). The incorporation of positively charged residues into
nisin has also had variable results [32,37,39,44]. Here, K12H and
K12R retained 75% and 61% activity, respectively (Table 3).
Thus, the effect of charge manipulation in nisin is difficult to
predict. The generally negative impact of introducing tyrosine,
tryptophan or phenylalanine at position K12 is also consistent with
previous reports regarding the incorporation of aromatic residues
into nisin [32,37,39,45,46] (Table 3). The incorporation of the
small hydrophobic residue glycine significantly decreased bioac-
tivity of the resultant derivative, while the remaining derivatives
had bioactivity comparable or improved relative to that of the
wild-type (Table 3). We noted that while the inclusion of
additional cysteine residues usually impacts negatively on
lantibiotic production and activity [37,39,47], in the case of
K12C bioactivity was comparable to that of the control (Table 3).
It should be noted that K12 has been the subject of previous
mutational analysis in both nisin A and nisin Z (nisin Z differs from
nisin A by the presence of an asparagine residue instead of a
histidine at position 27). The nisin Z K12P derivative was reported
to display antimicrobial properties that were similar to those of
nisin Z [48], but the nisin A K12P producer described in this study
had increased bioactivity relative to the corresponding wild-type
peptide against L. lactis HP (Table 3). In the current study, the
K12L producer displayed a level of bioactivity comparable to that
of the wild-type (Table 3) and a previous study indicated that this
mutation does not affect the specific activity of nisin A [49]. A nisin
Z K12S derivative was also previously created, and, as was the
case with nisin A K12S (Fig. 2), the larger portion of nisin Z K12S
remained unmodified. No impact on the antimicrobial activity of
nisin Z K12S was reported but, in that instance, bioactivity was
assessed against only one strain [50].
Our initial screen highlighted the marked enhancement in
bioactivity of the producers of nisin K12A, K12S and K12T
against L. lactis HP. This observation prompted further analysis
using a broad panel of Gram-positive microorganisms which
revealed superior bioactivity against numerous pathogens, includ-
ing S. aureus DPC5247 (a strain associated with bovine mastitis), S.
pyogenes DSM 11728 (a pharyngitis-associated clinical isolate), S.
Table 3. Mass Spectrometry Analysis and Bioactivity
Determination of Nisin K12X Bank.
Amino Acid Molecular Mass Bioactivity
K12X Predicted Observed Mean (S.D)
Hydrophilic:
Charged
Lysine+ve K 3353.06 3353.04 100 (N/A)
Histidine+ve H 3362.03 3361.40 75 (5)
Arginine+ve R 3381.08 3381.24 61 (6)
Glutamic acid -ve E 3354.01 3353.74 0 (N/A)
Aspartic acid -ve D 3339.98 ND 0 (N/A)
Hydrophilic:
Neutral
Threonine T 3326.00 3326.28
129 (3)
3307.98* 3307.63*
Serine S 3311.98 3311.14
128 (1)
3293.95* 3293.65*
Asparagine N 3339.00 3338.74 108 (9)
Glutamine Q 3353.03 3353.48 102 (9)
Tyrosine Y 3388.07 3388.43 73 (7)
Hydrophobic Alanine A 3295.98 3296.49 131 (2)
Proline P 3322.01 3321.71 118 (7)
Valine V 3324.03 3323.76 107 (9)
Methionine M 3356.08 3355.55 105 (9)
Cysteine C 3328.04 3328.89 103 (8)
Leucine L 3338.05 3339.02 89 (5)
Isoleucine I 3338.05 3337.88 89 (9)
Glycine G 3281.94 3281.90 68 (2)
Tryptophan W 3411.10 3410.83 63 (5)
Phenylalanine F 3372.07 3372.16 54 (5)
Observed molecular mass (+/20.25 Da) from MALDI-TOF MS analysis of NZ9800
pDF05-K12X producers. ND: not detected. * represents dehydrated forms
(hydrophobicmodified residues), i.e. Dhb in the case of T and Dha in the case of S.
Bioactivity of NZ9800 pDF05-K12X producers against L. lactis HP. Values given
are the mean of triplicate deferred antagonism assays and represent zone of
inhibition (diameter of zone minus diameter of bacterial growth) expressed as a
percentage compared to that of the wild-type nisin producer at 100%. S.D.:
Standard Deviation; Relative Standard Deviation ,10% for each given value. N/
A: not applicable. All values in bold reached statistical significance compared to
nisin control (K) (Student’s t-test: P,0.05).
doi:10.1371/journal.pone.0058530.t003
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agalactiae ATCC13813 (associated with early perinatal human
infections and bovine mastitis), as well as numerous drug resistant
strains (Table 4). The enhanced bioactivity of the K12A, K12S
and K12T producers did not extend to strains of L. monocytogenes,
with the exception of one mutant strain, EGD-e DvirR [51]
(Table 4). The VirRS two-component system contributes to the
regulation of a number of loci that play a role in innate nisin
resistance through the alteration of cell envelope charge
Table 4. Bioactivity of K12A, K12S and K12T producers against various Gram-positive targets.
Strain NisinK12A NisinK12S NisinK12T
Enterococcus faecalis 5152 211 (19) 164 (8) 181 (3)
Enterococcus casseliflavus 5053 174 (14) 169 (15) 166 (16)
Enterococcus faecium VRE EC533* 166 (2) 150 (6) 132 (11)
Enterococcus faecium VRE EC725* 143 (7) 124 (6) 117 (8)
Enterococcus faecium 5119 150 (9) 131 (0) 117 (9)
Enterococcus faecium 5137 140 (12) 121 (5) 125 (11)
Enterococcus durans 5133 127 (7) 118 (4) 121 (3)
Streptococcus dysgalactiae UCC 5003 175 (10) 147 (15) 136 (9)
Streptococcus dysgalactiae GroupC #2 145 (6) 123 (5) 113 (6)
Streptococcus pyogenes DSM 2071 170 (3) 143 (4) 137 (5)
Streptococcus pyogenes DSM 11728 132 (6) 122 (8) 119 (3)
Streptococcus pyogenes NCDO 2381 127 (10) 115 (1) 115 (3)
Streptococcus agalactiae ATCC 13813 142 (8) 123 (8) 120 (4)
Streptococcus agalactiae GroupB 134 (6) 124 (7) 127 (3)
Streptococcus agalactiae COH31rs 133 (6) 124 (11) 126 (11)
Streptococcus mitis UCC 5001 139 (4) 115 (8) 122 (10)
Bacillus cereus NCIMB 700578 167 (8) 162 (7) 158 (10)
Bacillus cereus NCIMB 700579 141 (3) 135 (6) 124 (11)
Bacillus cereus NCIMB 700827 133 (10) 120 (5) 117 (12)
Bacillus cereus DPC 6089 128 (10) 120 (4) 116 (4)
Bacillus cereus DPC 5334 126 (10) 110 (8) 105 (8)
Bacillus cereus NCIMB 700577 121 (10) 118 (10) 112 (6)
Bacillus subtilis UCC 5002 129 (7) 112 (4) 120 (7)
Lactococcus lactis MG1363 140 (3) 128 (7) 131 (7)
Staphylococcus aureus hVISA 32679* 140 (12) 132 (7) 124 (9)
Staphylococcus aureus hVISA 32652* 136 (3) 134 (3) 124 (5)
Staphylococcus aureus MRSA ST 534* 148 (9) 140 (14) 137 (10)
Staphylococcus aureus MRSA ST 528* 134 (6) 127 (5) 129 (7)
Staphylococcus aureus MRSA ST 530* 121 (1) 107 (3) 110 (1)
Staphylococcus aureus RF 122 130 (7) 124 (5) 120 (5)
Staphylococcus aureus DPC 5247 126 (3) 119 (3) 114 (5)
Staphylococcus aureus DPC 5971 124 (9) 116 (2) 111 (3)
Staphylococcus aureus NCDO 1499 111 (3) 109 (5) 109 (3)
Listeria monocytogenes EGD-e 106 (10) 97 (4) 100 (7)
Listeria monocytogenes EGD-eDvirR 133 (8) 122 (6) 121 (9)
Listeria monocytogenes EGD-eDtelA 93 (4) 91 (5) 95 (7)
Listeria monocytogenes L028 104 (6) 95 (5) 104 (10)
Listeria monocytogenes L028DgadA 101 (9) 98 (8) 89 (7)
Listeria monocytogenes L028 pORI19HK 99 (8) 102 (3) 106 (6)
Listeria monocytogenes 10403S 103 (8) 99 (9) 102 (5)
Listeria monocytogenes 33410 94 (7) 95 (9) 85 (8)
Listeria monocytogenes 33423 85 (6) 89 (0) 75 (6)
Values are the mean of triplicate deferred antagonism assays and represent zone of inhibition (diameter of zone minus diameter of bacterial growth) expressed as a
percentage compared to that of the wild-type nisin producer at 100%. S.D.: Standard Deviation; Relative Standard Deviation,10% for each given value. All values in
bold reached statistical significance compared to nisin control (K) (Student’s t-test: P,0.05). Strains marked with an asterisk are drug resistant isolates.
doi:10.1371/journal.pone.0058530.t004
Saturation Mutagenesis of K12 of Nisin A
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58530
[51,52,53,54]. It is thus unsurprising that mutation of virR, which
encodes the response regulator of this system, results in a strain
that is greatly sensitised to nisin [55]. The reason for the significant
bioactivity improvement of K12A, K12S and K12T relative to the
wild-type against L. monocytogenes EGD-e DvirR will be the subject
of further investigation. The strain variable nature of the enhanced
bioactivity of the individual derivatives provides further evidence
for the well-known phenomenon that nisin derivatives can be
generated with distinct target specificities.
Purification of K12S and K12T to enable specific activity
studies revealed that approximately twice as much K12S as
K12Dha was produced, whereas twice as much K12Dhb as K12T
was made (Fig. 2). While these hydroxyl residues are incorporated
at a non-native position, this observation is consistent with
previous suggestions that threonines in lantibiotics are more
frequently dehydrated than serines [56]. Interestingly, two
relatively new and highly potent members of the extended nisin
group, microbisporicin [57] and planosporicin [58], both possess a
Figure 2. RP-HPLC Separation of nisin A K12S/Dha and K12T/Dhb. Representative RP-HPLC peaks showing the appearance of A K12S and B
K12T after optimization of solvent gradient. Relative production levels were determined using triplicate peak areas from two independent
purifications from first principles. Relative Standard Deviation,12% for each given value.
doi:10.1371/journal.pone.0058530.g002
Table 5. Minimum inhibitory concentrations of purified nisin (WT) and nisin K12A against various Gram-positive targets.
Strain NisinA mg/L (nM) NisinK12A mg/L (nM) Fold Difference
E. faecalis 5152 25.15 (7500) 12.36 (3750) 2
E. casseliflavus 5053 12.57 (3750) 6.18 (1875) 2
E. faecium VRE EC 533 2.10 (625) 1.03 (312.5) 2
S. pyogenes DSM 2071 4.19 (1250) 2.06 (625) 2
S. mitis UCC 5001 8.38 (2500) 4.12 (1250) 2
B. cereus NCIMB 700578 8.38 (2500) 2.06 (625) 4
L. lactis HP 0.21 (62.5) 0.05 (15.6) 4
L. lactis MG 1363 0.42 (125) 0.21 (62.5) 2
S. aureus MRSA ST 534 1.05 (312.5) 0.52 (156.3) 2
Results from minimum inhibitory concentration assays of purified nisin (WT) and nisin K12A against various Gram-positive targets. Values given are identical results from
three independent determinations. Fold Difference represents the improvement of K12A compared to nisin against the relevant indicator.
doi:10.1371/journal.pone.0058530.t005
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threonine in place of lysine at position 12. It is also noteworthy
that the replacement of a natural lysine at position 22 with
hydroxyl residues (K22T, K22S) also resulted in enhanced
antimicrobial activity but, unlike the case of K12S and K12T,
neither of the newly incorporated residues were modified to any
detectable extent [37]. Unfortunately, nisin K12S, K12Dha,
K12T and K12Dhb were found to be particularly susceptible to
oxidation, thereby impeding accurate MIC determinations and
preventing an assessment of the relative contribution of the
individual peptides to the enhanced bioactivity of the K12S/Dha
and K12T/Dhb producers.
Ultimately, the K12A producer became the focus of further
study by MIC analysis utilising a variety of food-associated and
clinically significant strains. These assays revealed that K12A
displays a two- and four-fold improvement in specific activity
against the food-grade L. lactis strains MG1363 and HP,
respectively (Table 5). The two-fold improvement of K12A against
the Enterococcus isolates tested, including one VRE strain, is
particularly significant given that enterococci are ubiquitous in the
environment [59] and can cause nosocomial infections [60]. The
efficacy of K12A was improved two-fold against two clinical
Streptococcus isolates, including S. pyogenes DSM 2071 (Table 5), a
causative agent of streptococcal pharyngitis and its more serious
sequelae. Notably, K12A was also two-fold enhanced against a
strain of MRSA (Table 5). Finally, K12A showed a four-fold
increase in potency against a B. cereus strain (Table 5), a
microorganism that is widespread in soil and in foods and can
cause an emetic or a diarrhoeal type of food-associated illness [61].
Thus, MIC assays determined that the molecular basis for the
enhanced bioactivity of the nisin K12A producer is due to
improved specific activity of the mutant peptide against the Gram-
positive indicator strains tested. An agarose-based well diffusion
assay with purified peptide determined that the enhanced
spectrum of activity of K12A does not extend to include Gram-
negative bacteria (Table 6). Once again, these results highlight the
strain-variable nature of the improved activity possessed by many
nisin derivatives.
In conclusion, it is apparent that altering the K12 residue of
nisin A can generate derivatives with enhanced antimicrobial
activity. K12A has increased potency towards numerous food-
associated strains and the similar production levels of K12A to
nisin A suggests that the standard industrial nisin purification/
fermentation methods could be utilized. However, further studies
will be needed to investigate the physical and chemical properties
of K12A before it can be considered for use as a biopreservative,
including its solubility and stability at different temperatures and
varying pH. From a veterinary perspective, K12A appears to have
potential with respect to the treatment of bacteria that are
responsible for bovine mastitis (staphylococci and streptococci), as
well as showing promise as a novel candidate for treatment of S.
pyogenes infection. There is a pressing need for the development of
novel antimicrobials, especially given that infections now occur
that are resistant to all current antibacterial treatments [62]. The
improved specific activity of K12A towards MRSA ST528 and
VRE EC533 suggests that K12A merits further investigation with
respect to its application against such antibiotic resistant targets.
Future work will also focus on the elucidation of the mechanistic
basis for the enhanced activity of K12A relative to nisin, as well as
determining the effect of combining the K12A mutation with
other substitutions previously found to increase the potency of
nisin, alter its physico-chemical properties, or modify its activity
spectrum.
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